466 filings
Page 12 of 24
424B5
faptkcemysd7 p2jzss
3 Oct 17
Prospectus supplement for primary offering
12:00am
8-K
5y63wjbk
25 Sep 17
NewLink Genetics Announces Clinical Collaboration to Evaluate IO-Based Combination Therapies in Pancreatic Cancer
12:00am
8-K
w3qomo0q4u whbvx
7 Sep 17
Updated Data for Indoximod Plus KEYTRUDA® (pembrolizumab) Demonstrate Improvement of Response Rate for Patients with Advanced Melanoma
12:00am
8-K
rjmapbr
28 Jul 17
NewLink Genetics Reports Second Quarter 2017 Financial Results and Updates Indoximod Program
12:00am
8-K
ul0xhi486mr
27 Jul 17
NewLink Genetics Announces First Patient Dosed in Phase 1 Study of IDO Pathway Inhibitor NLG802
12:00am
8-K
5a4w7otf
17 Jul 17
Departure of Directors or Certain Officers
12:00am
8-K
2pcmr8bi5x6h
10 Jul 17
NewLink Genetics Receives Notice of Allowance from USPTO Covering Indoximod Salts and Prodrugs
12:00am
8-K
0g9 u68udp7f52
23 Jun 17
Other Events
12:00am
8-K
cp4e42 kix94dx9u5
8 Jun 17
Other Events
12:00am
8-K
z97p1j84t
5 Jun 17
Other Events
12:00am
8-K
40a6w
2 Jun 17
Results from Clinical Trial of Indoximod Plus Chemotherapy for Patients with Metastatic Breast Cancer
12:00am
8-K
4rmoja6cnpolb9pb
18 May 17
Other Events
12:00am
8-K
6l81fvbet6ae208
17 May 17
Submission of Matters to a Vote of Security Holders
12:00am
8-K
0wlwribxqwzci mxz5
17 May 17
Data from Clinical Studies of NewLink Genetics’ Two Distinct IDO Pathway Inhibitors to Be Presented at ASCO 2017
12:00am
8-K
uletj6th7i76oqnjk
4 May 17
NewLink Genetics Reports First Quarter 2017 Financial Results and Updates Clinical Trial Guidance
12:00am
8-K
ytlurmnofm4 ftebbdhu
4 Apr 17
Other Events
12:00am
DEFA14A
zb86go8
31 Mar 17
Additional proxy soliciting materials
12:00am